All News

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

I've found that making time for a good laugh each day helped break through the looming thought of cancer.

Dr. Dustin Deming, a gastrointestinal oncologist, began his own cancer journey more than a decade ago when he received a diagnosis of rectal cancer.

Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.

This study assessed the impact of laughter therapy in both patients with cancer and caregivers, and both groups showed decreases in mood disturbances, in addition to decreases in pain for patients and in burnout for caregivers.

After cancer, taking baby steps towards stuff you want to do is what matters.

The Food and Drug Administration is requesting that CAR-T cell therapies now come with a Boxed Warning about secondary malignancies that have been reported in patients who undergo these treatments.

“In my career of almost 30 years, I've never seen a liver cancer patient that did not have a chronic underlying liver disease,” Dr. Mindie H. Nguyen told CURE®.

Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.

Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

It’s important to know what kinds of treatments are available for bladder cancer and understand that having a “tailored” treatment is important for patients, experts said.

Getting a colonoscopy was the first step to gaining insight on my colon cancer.

Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.

Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.

Patients with unresectable hepatocellular carcinoma and poor liver function were more likely to experience serious side effects leading to regorafenib treatment discontinuation, researchers have found.

Dexter Scott King, son of Martin Luther King, Jr., died of prostate cancer the same day MLB Hall-of-Famer Ryan Sandberg announced he’s been diagnosed with metastatic disease.

Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab.

A cancer-related side effect I faced was constipation caused by pain medication.

In patients with esophageal squamous cell carcinoma, the combination of Tecentriq, tiragolumab and chemotherapy improved survival outcomes, research found.

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

In patients with TRK fusion GI cancers, Vitrakvi continued to show improvements regarding responses to treatment, survival and safety, research found.

Months after I was told I was in remission for stage 3B lung cancer, my "normal" shifted as the COVID-19 pandemic arrived.

Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma.

The use of FOLFOXIRI for metastatic colorectal cancer was lower than one what expert was expecting.

The use of the chemotherapy regimen FOLFOXIRI plus Avastin has increased from 2013 to 2022 in patients with metastatic colorectal cancer, particularly in patients aged 50 years and younger.

Certain patients with metastatic colorectal cancer were more likely to have long-term remission to Stivarga treatment, recent research showed.

After being diagnosed with Lynch syndrome, uncertainty has become a constant companion of mine.

Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers.